Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06929624 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

Name: A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma — clinical trial record (NCT06929624)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 3

SponsorSuzhou Suncadia Biopharmaceuticals Co., Ltd.

Started2025-04-24

View on ClinicalTrials.gov ↗

Amendment history

2026-09-26

Enrollment closed, study ongoing

2026-06-29

Study Status v3

Re-verified, no change to tracked fields

2025-11-14

Study Status, Contacts/Locations v2

Study sites1→2

2025-05-12

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-04→confirmed 2025-04-24

Study sitesdetails revised at 1 of 1 site

2025-04-08

Original filing

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

75 trials monitored

See 7 trials at risk

Non-Hodgkin Lymphoma

1,512 trials monitored

See 79 trials at risk

DLBCL

648 trials monitored

See 32 trials at risk

This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.

Trial Details

NCT Number	NCT06929624
Lead Sponsor	Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions	Diffuse Large B-cell Lymphoma
Enrollment	282 participants
Start Date	2025-04-24
Primary Completion	2027-03 (estimated)
Study Completion	2028-01 (estimated)
Updated on ClinicalTrials.gov	2026-09-25